Abstract

Highly Sensitive Direct Quantification of cfmiRNAs for Biomarker Profiling by Next Generation Sequencing (NGS)

Sergio Barberan Soler, Director of Sequencing Technologies, Somagenics, Inc

Cell-free miRNAs (cf-miRNAs) are promising diagnostic and prognostic biomarkers for cancer and other diseases. cf-miRNAs are highly stable in biofluids and more attractive for NGS- based detection compared to, other more labile biomolecules. However, NGS miRNA detection from biofluids is limited by highly biased, error prone library preparation technologies. RealSeq® addresses these issues with proven best in class accuracy of detection [1]. This novel platform includes a kit designed to profile miRNAs from biofluids (RealSeq®-Biofluids) with a four-fold increase in number of miRNAs detected over commercially available technologies. Additionally, we have developed RealSeq®-T, the first and only targeted sequencing approach to detect panels of cf-miRNAs (up to 1,200) directly from plasma (no RNA extraction) demonstrating nearly 95% of sequenced reads mapped to the miRNA panel. The RealSeq® technology platform facilitates the use of cf-miRNAs as clinical biomarkers for liquid biopsy applications.